Business Description
Sunshine Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US8677811064
Description
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.96 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.91 | |||||
| Beneish M-Score | -0.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 204.7 | |||||
| 3-Year EBITDA Growth Rate | 50.3 | |||||
| 3-Year EPS without NRI Growth Rate | -73.4 | |||||
| 3-Year FCF Growth Rate | -6.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.41 | |||||
| 9-Day RSI | 45.18 | |||||
| 14-Day RSI | 47.33 | |||||
| 3-1 Month Momentum % | -6.07 | |||||
| 6-1 Month Momentum % | -53.89 | |||||
| 12-1 Month Momentum % | -99.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.74 | |||||
| Quick Ratio | 3.57 | |||||
| Cash Ratio | 2.7 | |||||
| Days Inventory | 116.03 | |||||
| Days Sales Outstanding | 32.35 | |||||
| Days Payable | 56.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -152.5 | |||||
| Shareholder Yield % | -91.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 30.78 | |||||
| Operating Margin % | -14.9 | |||||
| Net Margin % | -12.82 | |||||
| FCF Margin % | -42.48 | |||||
| ROE % | -18.13 | |||||
| ROA % | -14.45 | |||||
| ROIC % | -57.95 | |||||
| 3-Year ROIIC % | -100.62 | |||||
| ROC (Joel Greenblatt) % | -60.31 | |||||
| ROCE % | -16.91 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 3.66 | |||||
| PB Ratio | 0.22 | |||||
| Price-to-Tangible-Book | 0.25 | |||||
| EV-to-EBIT | 1.45 | |||||
| EV-to-EBITDA | 1.53 | |||||
| EV-to-Revenue | -0.18 | |||||
| EV-to-FCF | 0.42 | |||||
| Price-to-Net-Current-Asset-Value | 0.26 | |||||
| Price-to-Net-Cash | 0.75 | |||||
| Earnings Yield (Greenblatt) % | 68.97 | |||||
| FCF Yield % | -258.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SBFM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sunshine Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 32.959 | ||
| EPS (TTM) ($) | -155.329 | ||
| Beta | 1.69 | ||
| 3-Year Sharpe Ratio | -1.42 | ||
| 3-Year Sortino Ratio | -1.55 | ||
| Volatility % | 111.25 | ||
| 14-Day RSI | 47.33 | ||
| 14-Day ATR ($) | 0.309792 | ||
| 20-Day SMA ($) | 2.70575 | ||
| 12-1 Month Momentum % | -99.49 | ||
| 52-Week Range ($) | 2.1056 - 608 | ||
| Shares Outstanding (Mil) | 2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sunshine Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sunshine Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sunshine Biopharma Inc Frequently Asked Questions
What is Sunshine Biopharma Inc(SBFM)'s stock price today?
The current price of SBFM is $2.71. The 52 week high of SBFM is $608.00 and 52 week low is $2.11.
When is next earnings date of Sunshine Biopharma Inc(SBFM)?
The next earnings date of Sunshine Biopharma Inc(SBFM) is 2025-02-05 Est..
Does Sunshine Biopharma Inc(SBFM) pay dividends? If so, how much?
Sunshine Biopharma Inc(SBFM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers